BiotechTube

Somapacitan + Norditropin®

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SGA, Turner Syndrome, Noonan Syndrome, ISS

Conditions

SGA, Turner Syndrome, Noonan Syndrome, ISS

Trial Timeline

Aug 10, 2022 → Oct 29, 2027

NCT ID
NCT05330325

About Somapacitan + Norditropin®

Somapacitan + Norditropin® is a phase 3 stage product being developed by Novo Nordisk for SGA, Turner Syndrome, Noonan Syndrome, ISS. The current trial status is active. This product is registered under clinical trial identifier NCT05330325. Target conditions include SGA, Turner Syndrome, Noonan Syndrome, ISS.

What happened to similar drugs?

3 of 7 similar drugs in SGA, Turner Syndrome, Noonan Syndrome, ISS were approved

Approved (3) Terminated (0) Active (4)
✅HumatropeEli LillyApproved
✅r-hGHMerckApproved
✅estradiolNovo NordiskApproved
🔄SomatropinEli LillyPhase 3
🔄17 beta estradiolEli LillyPhase 3
🔄Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
🔄Somatropin (rDNA origin)IpsenPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT05330325Phase 3Active
NCT04970654Phase 3Completed
NCT03878446Phase 2Active
NCT03811535Phase 3Completed

Competing Products

10 competing products in SGA, Turner Syndrome, Noonan Syndrome, ISS

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
HumatropeEli LillyApproved
43
17 beta estradiolEli LillyPhase 3
40
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
40
r-hGHMerckApproved
43
estradiolNovo NordiskApproved
43
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
21
somatotropinPfizerPre-clinical
26
Lonapegsomatropin + SomatropinAscendis PharmaPhase 2
36
Somatropin (rDNA origin)IpsenPhase 3
37